<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Clinical Trial Insights</title>
  <style>
    body { font-family: Arial, sans-serif; padding: 2rem; background: #f5f6fa; }
    table { border-collapse: collapse; width: 100%; background: white; box-shadow: 0 2px 8px rgba(0,0,0,0.08); }
    th, td { padding: 0.6rem 0.9rem; text-align: left; border-bottom: 1px solid #e1e4eb; }
    th { background: #0f6db5; color: white; }
    tr:hover { background: #f0f8ff; }
  </style>
</head>
<body>
  <h1>Lab Demand Signals</h1>
  <table>
    <tr>
      <th>Principal investigator</th>
      <th>Email</th>
      <th>Product</th>
      <th>Demand signal</th>
      <th>Demand reason</th>
      <th>Trial</th>
      <th>Detected at</th>
    </tr>
    <tr><td>Pfizer</td><td></td><td>PARP Inhibitor Capsules</td><td>High</td><td>Used as the active drug in the experimental arm for DDR-deficient mCSPC patients.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Pfizer</td><td></td><td>Androgen Receptor Inhibitor Capsules</td><td>High</td><td>Used as open-label treatment in combination with talazoparib or placebo.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Pfizer</td><td></td><td>Placebo Capsules</td><td>High</td><td>Used as placebo control in the comparator arm, identical in appearance to talazoparib capsules.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Pfizer</td><td></td><td>Plasma Collection Tubes</td><td>Medium</td><td>Required for pharmacokinetic assessments of talazoparib, enzalutamide, and its metabolite.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Pfizer</td><td></td><td>Cell-Free DNA Extraction Kits</td><td>Medium</td><td>Used for extraction of ctDNA from plasma samples to assess ctDNA burden.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Pfizer</td><td></td><td>DNA Mutation Detection Assays</td><td>Medium</td><td>Used to detect DDR gene mutations in ctDNA for patient stratification and outcome correlation.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Pfizer</td><td></td><td>Patient-Reported Outcome Questionnaires</td><td>Low</td><td>Used to assess cancer-specific global health status, symptoms, and quality of life.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Pfizer</td><td></td><td>Pain Inventory Questionnaires</td><td>Low</td><td>Used to assess patient-reported pain symptoms and time to deterioration.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Cortisol ELISA Kits</td><td>High</td><td>Required to measure cortisol levels in urine and saliva samples to assess UFC and LNSC endpoints.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Anti-Drug Antibody (ADA) Detection Kits</td><td>High</td><td>Needed to detect anti-drug antibodies against Lu AG13909 in participant plasma samples.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Pharmacokinetic Assay Kits</td><td>Medium</td><td>Used to quantify plasma concentrations of Lu AG13909 for pharmacokinetic parameters (AUC, Cmax, Tmax, t½, Vd, CL).</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Urine Collection Tubes with Preservative</td><td>Medium</td><td>Required for collection and preservation of urine samples for UFC measurement.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Saliva Collection Devices</td><td>Medium</td><td>Needed for collection of late night salivary cortisol samples (LNSC) to assess cortisol response.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Urine Drug Test Kits</td><td>High</td><td>Required for detecting opioids and other nonmedical substances in participant urine samples at multiple time points (Day 1, Day 4, Week 2, Week 4, Week 8).</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Polysomnography Electrodes</td><td>Medium</td><td>Used to measure total sleep time and wakefulness after persistent sleep onset in the sleep laboratory.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Polysomnography Sensors</td><td>Medium</td><td>Required for comprehensive polysomnography to assess sleep parameters in participants.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Questionnaire Forms</td><td>Low</td><td>Self-reported questionnaire to assess nonmedical substance and alcohol use at multiple study visits.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Drugs</td><td>High</td><td>Investigational drug administered orally once daily to participants with advanced RCC.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Drugs</td><td>High</td><td>Investigational drug administered orally once daily in combination with belzutifan.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Drugs</td><td>High</td><td>Comparator drug administered orally once daily to participants with advanced RCC.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>RECIST 1.1 Imaging Analysis Software</td><td>Medium</td><td>Used to assess tumor response and progression by measuring lesion diameters per RECIST 1.1 criteria.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Blinded Independent Central Review (BICR) Services</td><td>Medium</td><td>Independent review of imaging data to assess progression-free survival and response rates.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Quality of Life (QoL) Questionnaires</td><td>Medium</td><td>Cancer-specific QoL questionnaire used to assess global health, physical and role functioning.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Symptom Index Questionnaires</td><td>Medium</td><td>9-item questionnaire assessing kidney cancer symptom burden in participants.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Antibody-Drug Conjugates</td><td>High</td><td>Study treatment administered via IV infusion to pediatric participants with relapsed or refractory solid tumors.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Plasma Collection Tubes</td><td>High</td><td>Used for blood sample collection at specified intervals for pharmacokinetic analyses (AUC, Cmax, Ctrough) of anti-HER3 antibody, anti-HER3-ac-DXd, and DXd in plasma.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>LC-MS Reagents</td><td>High</td><td>Required for liquid chromatography-mass spectrometry analysis to quantify anti-HER3 antibody, anti-HER3-ac-DXd, and DXd in plasma samples.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Cell Lines</td><td>Medium</td><td>Used for in vitro testing and validation of patritumab deruxtecan efficacy against hepatoblastoma.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Cell Lines</td><td>Medium</td><td>Used for in vitro testing and validation of patritumab deruxtecan efficacy against rhabdomyosarcoma.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Immunoassay Kits</td><td>Medium</td><td>Used to measure anti-HER3 antibody levels in plasma samples as part of pharmacokinetic assessments.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Jessica Tao, MD</td><td></td><td>CDK4/6 Inhibitors</td><td>High</td><td>Palbociclib is the primary drug being administered orally to participants to evaluate progression-free survival.</td><td>Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Jessica Tao, MD</td><td></td><td>Selective Estrogen Receptor Downregulators (SERDs)</td><td>High</td><td>Fulvestrant is administered intramuscularly to participants in combination with palbociclib.</td><td>Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Jessica Tao, MD</td><td></td><td>DNA Extraction Kits</td><td>High</td><td>Used to extract circulating plasma tumor DNA (ptDNA) from blood samples for mutation analysis.</td><td>Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Jessica Tao, MD</td><td></td><td>PCR Mutation Detection Kits</td><td>High</td><td>Used to detect ESR1 mutations in tumor biopsies and ptDNA samples.</td><td>Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Jessica Tao, MD</td><td></td><td>PCR Mutation Detection Kits</td><td>High</td><td>Used to detect PI3K mutations in tumor biopsies and ptDNA samples.</td><td>Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Jessica Tao, MD</td><td></td><td>Phosphoprotein Detection Antibodies</td><td>Medium</td><td>Used to identify novel activated protein kinases in tumor biopsy samples.</td><td>Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Jessica Tao, MD</td><td></td><td>Immunohistochemistry (IHC) Antibodies</td><td>Medium</td><td>Used for IHC staining of tumor biopsies to assess ER status and correlate with mutation data.</td><td>Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Jessica Tao, MD</td><td></td><td>Immunohistochemistry (IHC) Antibodies</td><td>Medium</td><td>Used to profile candidate phosphoprotein expression in tumor biopsies.</td><td>Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Amir Jazaeri, M D</td><td></td><td>Monoclonal Antibodies</td><td>High</td><td>Therapeutic monoclonal antibody administered intravenously to patients as part of the trial treatment.</td><td>Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Amir Jazaeri, M D</td><td></td><td>Small Molecule Inhibitors</td><td>High</td><td>Small molecule PP2A inhibitor administered intravenously to patients as part of the trial treatment.</td><td>Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Amir Jazaeri, M D</td><td></td><td>Immunohistochemistry (IHC) Antibodies</td><td>High</td><td>Used to assess expression of mismatch repair proteins in tumor biopsy samples by IHC.</td><td>Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Amir Jazaeri, M D</td><td></td><td>PBMC Isolation Kits</td><td>High</td><td>Required to isolate PBMCs from patient blood samples for immune monitoring and PP2A activity assays.</td><td>Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Amir Jazaeri, M D</td><td></td><td>ctDNA Extraction Kits</td><td>Medium</td><td>Used to extract ctDNA from plasma samples to correlate ctDNA levels with tumor response.</td><td>Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Amir Jazaeri, M D</td><td></td><td>PP2A Activity Assay Kits</td><td>Medium</td><td>Used to measure PP2A enzyme activity in tumor biopsy and PBMC samples.</td><td>Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Amir Jazaeri, M D</td><td></td><td>Cell Lines</td><td>Medium</td><td>Used for in vitro validation and mechanistic studies related to PP2A targeting and drug response.</td><td>Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Kristin E Rojas, MD</td><td></td><td>Platelet-Rich Plasma Preparation Kits</td><td>High</td><td>Essential for preparing platelet-rich plasma injections used in treatment sessions for GSM symptoms.</td><td>A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Kristin E Rojas, MD</td><td></td><td>Sterile Syringes and Needles</td><td>Medium</td><td>Required for precise injection of 0.1-0.2 mL PRP into vulvovaginal mucosa.</td><td>A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Kristin E Rojas, MD</td><td></td><td>Validated Clinical Questionnaires</td><td>Low</td><td>Used to assess changes in GSM symptoms via patient self-report.</td><td>A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Kristin E Rojas, MD</td><td></td><td>Validated Clinical Questionnaires</td><td>Low</td><td>Used to evaluate postmenopausal vaginal health symptoms such as dryness and irritation.</td><td>A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Kristin E Rojas, MD</td><td></td><td>Validated Clinical Questionnaires</td><td>Low</td><td>Measures sexual function changes in participants.</td><td>A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Kristin E Rojas, MD</td><td></td><td>Validated Clinical Questionnaires</td><td>Low</td><td>Assesses sexual-related distress in participants.</td><td>A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Grifols Therapeutics LLC</td><td></td><td>Human Serum Albumin Solution</td><td>High</td><td>Main replacement fluid for plasma exchange (PE-A 5%) administered intravenously to subjects in the treatment group.</td><td>Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Grifols Therapeutics LLC</td><td></td><td>Fresh Frozen Plasma</td><td>High</td><td>Administered after each PE-A 5% session to prevent coagulopathy in treatment group subjects.</td><td>Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Grifols Therapeutics LLC</td><td></td><td>Intravenous Immunoglobulin (IVIG)</td><td>High</td><td>Administered intravenously to prevent hypogammaglobulinemia and infection in treatment group subjects.</td><td>Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Emmanuel Flamand-Roze, MD, PhD</td><td></td><td>Triglyceride Oils</td><td>High</td><td>Active drug tested for efficacy in AHC patients, administered orally in multiple doses.</td><td>"Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant" HEMIHEP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Emmanuel Flamand-Roze, MD, PhD</td><td></td><td>Placebo Oils</td><td>High</td><td>Placebo control for double-blind crossover design, administered orally in multiple doses.</td><td>"Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant" HEMIHEP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Emmanuel Flamand-Roze, MD, PhD</td><td></td><td>Acylcarnitine Profiling Kits</td><td>Medium</td><td>Used to measure biological safety endpoints related to fatty acid metabolism.</td><td>"Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant" HEMIHEP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Emmanuel Flamand-Roze, MD, PhD</td><td></td><td>Organic Acid Quantification Kits</td><td>Medium</td><td>Used to assess biological safety by measuring organic acid levels in patient samples.</td><td>"Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant" HEMIHEP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Emmanuel Flamand-Roze, MD, PhD</td><td></td><td>31Phosphorus MRS Contrast Agents</td><td>Low</td><td>Used during brain 31P MRS to measure Pi/Phosphocreatine ratio under visual stimulation.</td><td>"Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant" HEMIHEP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>DNA Demethylating Agents</td><td>High</td><td>Primary investigational drug administered as inhaled aerosol for 3 cycles (3 days each) to up to 52 participants.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>Immune Checkpoint Inhibitors</td><td>High</td><td>Administered intravenously on day 4 of each cycle as part of combined chemo-immunotherapy regimen.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>Platinum-Based Chemotherapy Agents</td><td>High</td><td>Two-drug platinum-based chemotherapy administered IV on day 4 of each cycle for 3 cycles.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>Nebulizers</td><td>Medium</td><td>Device used to deliver inhaled azacytidine aerosol to participants during treatment days.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>Tissue Biopsy Kits</td><td>Medium</td><td>Required for pre-treatment and post-treatment tumor tissue sampling and airway biopsies.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>Bronchoalveolar Lavage (BAL) Fluid Collection Kits</td><td>Medium</td><td>Used to collect bronchial lavage fluid for immune cell phenotype and cytokine analysis.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>RNA Extraction Kits</td><td>Medium</td><td>For extraction of RNA from tumor biopsies to analyze DNMT, CTA, and immune-related gene expression.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>DNA Methylation Assay Kits</td><td>Medium</td><td>Used to assess DNA methylation changes in tumor tissue samples pre- and post-treatment.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>Flow Cytometry Antibodies</td><td>Low</td><td>For immune cell phenotype analysis in pulmonary lavage fluid samples.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>David S Schrump, M.D.</td><td></td><td>Cytokine ELISA Kits</td><td>Low</td><td>To measure cytokine levels in bronchial lavage fluid as part of immune response assessment.</td><td>Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Monoclonal Antibodies</td><td>High</td><td>Pembrolizumab is the key immunotherapy drug administered every 6 weeks for up to 18 cycles in both study arms.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Antibody-Drug Conjugates</td><td>High</td><td>Sacituzumab tirumotecan is administered via IV infusion on Days 1, 15, and 29 of each 6-week cycle in combination arm.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Antihistamines</td><td>Medium</td><td>Used as premedication prior to the first 4 infusions of sacituzumab tirumotecan to prevent infusion reactions.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>H2 Receptor Antagonists</td><td>Medium</td><td>Optional premedication prior to first 4 infusions of sacituzumab tirumotecan to reduce infusion-related side effects.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Analgesics</td><td>Medium</td><td>Premedication prior to first 4 infusions of sacituzumab tirumotecan to mitigate infusion reactions.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Corticosteroids</td><td>Medium</td><td>Premedication prior to first 4 infusions of sacituzumab tirumotecan; optional at subsequent infusions.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Antiemetic Agents</td><td>Medium</td><td>Supportive care to manage nausea and vomiting during treatment.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Antidiarrheal Agents</td><td>Medium</td><td>Supportive care to manage diarrhea during treatment.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Hematopoietic Growth Factors</td><td>Medium</td><td>Supportive care to manage neutropenia and anemia during treatment.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Blood Products</td><td>Medium</td><td>Supportive care for participants requiring transfusions due to treatment-related cytopenias.</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Oral Tablets</td><td>High</td><td>Active drug administered once daily for up to 104 weeks to participants with FSGS.</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Oral Tablets</td><td>High</td><td>Placebo tablets identical in appearance to BI 764198 used for control group.</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Urine Collection Containers</td><td>High</td><td>Used for collection of 24-hour urine samples to measure protein-to-creatinine ratio (UPCR).</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Creatinine Assay Kits</td><td>High</td><td>Used to quantify creatinine levels in urine samples for UPCR calculation.</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Protein Quantification Kits</td><td>High</td><td>Used to measure urinary protein concentration for UPCR endpoint.</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Serum Cystatin C Assay Kits</td><td>High</td><td>Used to measure serum cystatin C for eGFRcys calculation.</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Blood Collection Tubes</td><td>Medium</td><td>Used for blood collection to obtain serum for cystatin C measurement.</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Quality of Life Survey Kits</td><td>Medium</td><td>Materials for administering Kidney Disease Quality of Life 36-item survey to participants.</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Boehringer Ingelheim</td><td></td><td>Symptom Assessment Questionnaires</td><td>Medium</td><td>Questionnaire materials to assess swelling impact in participants with nephrotic syndrome.</td><td>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Gritgen Therapeutics Co., Ltd.</td><td></td><td>AAV8 Viral Vector</td><td>High</td><td>Core investigational gene therapy vector for intravenous administration to express B-domain deleted human FVIII in hepatocytes.</td><td>A Single-arm, Open-label, Multicenter Study Evaluating the Efficacy and Safety of GS1191-0445 Injection as a Single Dose in Chinese Subjects With Hemophilia A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Gritgen Therapeutics Co., Ltd.</td><td></td><td>Human Factor VIII ELISA Kit</td><td>High</td><td>To measure FVIII activity levels in plasma samples post GS1191-0445 administration for efficacy evaluation.</td><td>A Single-arm, Open-label, Multicenter Study Evaluating the Efficacy and Safety of GS1191-0445 Injection as a Single Dose in Chinese Subjects With Hemophilia A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Gritgen Therapeutics Co., Ltd.</td><td></td><td>Anti-AAV8 Capsid Antibody Detection Kit</td><td>High</td><td>To evaluate immunogenic response against AAV8 capsid protein within 52 weeks post infusion.</td><td>A Single-arm, Open-label, Multicenter Study Evaluating the Efficacy and Safety of GS1191-0445 Injection as a Single Dose in Chinese Subjects With Hemophilia A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Gritgen Therapeutics Co., Ltd.</td><td></td><td>Human Cytokine Multiplex Assay Kit</td><td>Medium</td><td>To monitor immune activation and adverse events related to gene therapy administration.</td><td>A Single-arm, Open-label, Multicenter Study Evaluating the Efficacy and Safety of GS1191-0445 Injection as a Single Dose in Chinese Subjects With Hemophilia A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Gritgen Therapeutics Co., Ltd.</td><td></td><td>Hepatocyte Cell Line</td><td>Medium</td><td>In vitro model for studying AAV8 transduction efficiency and FVIII expression under liver-specific promoter.</td><td>A Single-arm, Open-label, Multicenter Study Evaluating the Efficacy and Safety of GS1191-0445 Injection as a Single Dose in Chinese Subjects With Hemophilia A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Monoclonal Antibodies</td><td>High</td><td>Pembrolizumab is the key immunotherapy drug administered intravenously every 6 weeks for up to 18 cycles in the trial.</td><td>A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Tyrosine Kinase Inhibitors</td><td>High</td><td>Lenvatinib is administered orally daily during induction and consolidation phases as part of the combination therapy.</td><td>A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Platinum-based Chemotherapy Agents</td><td>High</td><td>Cisplatin is used in FP and TP chemotherapy regimens administered intravenously every 3 weeks or 2 weeks depending on regimen.</td><td>A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Antimetabolite Chemotherapy Agents</td><td>High</td><td>5-FU is administered intravenously as part of FP and mFOLFOX6 chemotherapy regimens with bolus and continuous infusion schedules.</td><td>A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Taxane Chemotherapy Agents</td><td>High</td><td>Paclitaxel is used in the TP chemotherapy regimen administered intravenously every 3 weeks.</td><td>A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Platinum-based Chemotherapy Agents</td><td>Medium</td><td>Oxaliplatin is part of the mFOLFOX6 chemotherapy regimen administered intravenously every 2 weeks.</td><td>A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Folate Analogues</td><td>Medium</td><td>Leucovorin is used in the mFOLFOX6 regimen to enhance 5-FU efficacy, administered intravenously every 2 weeks.</td><td>A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Folate Analogues</td><td>Medium</td><td>Levoleucovorin is an alternative folate analogue used in the TP chemotherapy regimen administered intravenously every 3 weeks.</td><td>A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Oncolytic Viral Vectors</td><td>High</td><td>Primary investigational agent administered intraperitoneally in Arm A for tumor cell killing and imaging.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Chemotherapy Agents</td><td>High</td><td>One of the investigator's choice chemotherapy drugs administered IV in Arm B.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Chemotherapy Agents</td><td>High</td><td>Investigator's choice chemotherapy drug administered IV on days 1, 8, and 15 in Arm B.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Chemotherapy Agents</td><td>High</td><td>Investigator's choice chemotherapy drug administered IV on days 1, 8, and 15 in Arm B.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Chemotherapy Agents</td><td>High</td><td>Investigator's choice chemotherapy drug administered IV on days 1, 8, and 15 in Arm B.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Monoclonal Antibodies</td><td>Medium</td><td>Optional monoclonal antibody administered IV with certain chemotherapy regimens in Arm B.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Immune Assay Kits</td><td>Medium</td><td>Used to measure immune responses to MV-NIS in translational objectives.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>RNA Extraction Kits</td><td>Medium</td><td>Required for transcriptomic analysis of tumor biopsy specimens.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Radiopharmaceuticals</td><td>Medium</td><td>Used for SPECT/CT imaging to assess biodistribution of MV-NIS expressing sodium iodide symporter.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Evanthia Galanis, M.D.</td><td></td><td>Cell Lines</td><td>Medium</td><td>For in vitro validation and mechanistic studies related to MV-NIS and chemotherapy effects.</td><td>MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Hoffmann-La Roche</td><td></td><td>Small Molecule Kinase Inhibitors</td><td>High</td><td>Primary investigational drug administered orally in combination regimens for PIK3CA-mutated breast cancer patients.</td><td>A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Hoffmann-La Roche</td><td></td><td>Aromatase Inhibitors</td><td>High</td><td>Used orally in combination with inavolisib and ribociclib for ER-positive breast cancer treatment.</td><td>A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Hoffmann-La Roche</td><td></td><td>CDK4/6 Inhibitors</td><td>High</td><td>Administered orally in combination with inavolisib and letrozole to inhibit cell cycle progression in breast cancer cells.</td><td>A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Hoffmann-La Roche</td><td></td><td>Immunohistochemistry (IHC) Kits</td><td>Medium</td><td>Used to measure changes in Ki-67 proliferation marker levels in tumor biopsy samples as a biomarker of treatment response.</td><td>A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Hoffmann-La Roche</td><td></td><td>mRECIST v1.1 Assessment Kits</td><td>Medium</td><td>Used to assess objective response rate (ORR) according to modified RECIST criteria in imaging studies.</td><td>A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Hoffmann-La Roche</td><td></td><td>Patient-Reported Outcome (PRO) Questionnaires</td><td>Low</td><td>Used to assess treatment side-effect bother and quality of life in participants.</td><td>A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Hoffmann-La Roche</td><td></td><td>PRO-CTCAE Questionnaires</td><td>Low</td><td>Used to collect patient-reported adverse event symptoms and toxicities during treatment.</td><td>A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Denise L Faustman, MD, PhD</td><td></td><td>Live Attenuated Vaccines</td><td>High</td><td>Primary intervention agent for repeat vaccinations to treat Type 1 diabetes by targeting disease-causing white blood cells.</td><td>Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Denise L Faustman, MD, PhD</td><td></td><td>Sterile Saline Solutions</td><td>High</td><td>Placebo control injections for double-blinded trial design.</td><td>Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Denise L Faustman, MD, PhD</td><td></td><td>HbA1c Assay Kits</td><td>Medium</td><td>To measure changes in hemoglobin A1c values as a metabolic endpoint in juvenile onset Type 1 diabetics.</td><td>Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Denise L Faustman, MD, PhD</td><td></td><td>C-Peptide ELISA Kits</td><td>Medium</td><td>To quantify endogenous insulin secretion by measuring c-peptide levels in blood samples.</td><td>Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Denise L Faustman, MD, PhD</td><td></td><td>Proinsulin ELISA Kits</td><td>Medium</td><td>To measure proinsulin levels as an analog for endogenous insulin in blood samples.</td><td>Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Denise L Faustman, MD, PhD</td><td></td><td>Autoantibody Detection Kits</td><td>Medium</td><td>To monitor autoantibodies and autoreactive T cells for assessing autoimmune changes during treatment.</td><td>Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Servier Bio-Innovation LLC</td><td></td><td>S-adenosylmethionine (SAM) Quantification Kits</td><td>High</td><td>Required to measure plasma concentrations of SAM to assess pharmacodynamic effects of MAT2A inhibition in Phase 1.</td><td>A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Servier Bio-Innovation LLC</td><td></td><td>Symmetric Dimethylarginine (SDMA) Assay Kits</td><td>High</td><td>Needed to quantify tumor symmetric dimethylarginine residues as a biomarker of PRMT5 inhibition in Phase 1.</td><td>A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Servier Bio-Innovation LLC</td><td></td><td>Cell Lines</td><td>High</td><td>Used for in vitro validation and pharmacokinetic/pharmacodynamic studies of S095035 and TNG462 targeting MTAP-deleted tumors.</td><td>A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Servier Bio-Innovation LLC</td><td></td><td>RECIST 1.1 and RANO 2.0 Imaging Analysis Software Licenses</td><td>Medium</td><td>Required for objective response rate and tumor response assessments by investigators and blinded independent central review.</td><td>A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Servier Bio-Innovation LLC</td><td></td><td>Pharmacokinetic Assay Kits</td><td>Medium</td><td>Needed for measuring plasma drug concentrations to calculate pharmacokinetic parameters such as AUC, Cmax, Tmax, half-life, clearance.</td><td>A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Monoclonal Antibodies</td><td>High</td><td>Pembrolizumab is administered IV on Day 1 of each 6-week cycle for up to 17 cycles as part of the treatment regimen.</td><td>A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Antibody-Drug Conjugates</td><td>High</td><td>Zilovertamab vedotin is administered IV on Day 1 and Day 8 of each 3-week cycle until disease progression or discontinuation.</td><td>A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Monoclonal Antibodies</td><td>High</td><td>MK-3120 is administered IV on Day 1, Day 15, and Day 29 of each 6-week cycle until disease progression or discontinuation.</td><td>A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>RECIST 1.1 Tumor Measurement Kits</td><td>Medium</td><td>Required for assessing tumor response per RECIST 1.1 criteria including measurement of target lesions.</td><td>A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Adverse Event Monitoring Kits</td><td>Medium</td><td>Used to monitor and document adverse events related to study treatments.</td><td>A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Benjamin L Maughan</td><td></td><td>Monoclonal Antibodies</td><td>High</td><td>Used as immunotherapy agent administered IV in combination arm to treat metastatic papillary renal cell carcinoma.</td><td>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Benjamin L Maughan</td><td></td><td>Kinase Inhibitors</td><td>High</td><td>Orally administered kinase inhibitor used in both arms to inhibit tumor growth and angiogenesis.</td><td>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Benjamin L Maughan</td><td></td><td>Blood Collection Tubes</td><td>Medium</td><td>Required for collection of blood samples for biomarker and correlative studies.</td><td>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Benjamin L Maughan</td><td></td><td>Urine Collection Containers</td><td>Medium</td><td>Used for urine sample collection throughout the trial for biomarker analysis.</td><td>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Benjamin L Maughan</td><td></td><td>Cryopreservation Media</td><td>Medium</td><td>Used for banking biospecimens for future correlative studies.</td><td>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Benjamin L Maughan</td><td></td><td>Imaging Contrast Agents</td><td>Low</td><td>Used during CT scans to enhance imaging of tumors.</td><td>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Benjamin L Maughan</td><td></td><td>MRI Contrast Agents</td><td>Low</td><td>Used during MRI scans to improve visualization of tumor lesions.</td><td>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Benjamin L Maughan</td><td></td><td>Bone Scan Radiotracers</td><td>Low</td><td>Used for bone scans to detect metastatic spread to bone.</td><td>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Maria Liza Lindenberg, M.D.</td><td></td><td>Radiopharmaceuticals</td><td>High</td><td>Primary PET imaging tracer targeting CXCR4 to identify functional adrenal tumors in study participants.</td><td>Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Maria Liza Lindenberg, M.D.</td><td></td><td>PET Imaging Contrast Agents</td><td>High</td><td>Required for PET/CT or PET/MR imaging to enhance visualization of adrenal tumors alongside [68Ga]Ga-PentixaFor.</td><td>Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Maria Liza Lindenberg, M.D.</td><td></td><td>Immunohistochemistry (IHC) Antibodies</td><td>Medium</td><td>Used to measure CXCR4 expression in resected adrenal tissue samples for correlation with PET imaging results.</td><td>Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Maria Liza Lindenberg, M.D.</td><td></td><td>Blood Collection Tubes</td><td>Medium</td><td>Used for blood sample collection to monitor hormone levels and safety labs before and after tracer injection.</td><td>Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Maria Liza Lindenberg, M.D.</td><td></td><td>Hormone Assay Kits</td><td>Medium</td><td>To quantify aldosterone levels in participants as part of eligibility and correlative biochemical analysis.</td><td>Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Maria Liza Lindenberg, M.D.</td><td></td><td>Hormone Assay Kits</td><td>Medium</td><td>To quantify cortisol levels in participants as part of eligibility and correlative biochemical analysis.</td><td>Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Maria Liza Lindenberg, M.D.</td><td></td><td>Intravenous Catheters</td><td>Low</td><td>Used for intravenous administration of [68Ga]Ga-PentixaFor tracer prior to PET imaging.</td><td>Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Nicolas Chevalier</td><td></td><td>Recombinant FSH (Follitropin Delta)</td><td>High</td><td>Primary ovarian stimulation drug used at fixed dose of 3.66 mcg for controlled ovarian stimulation in IUI.</td><td>Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Nicolas Chevalier</td><td></td><td>hCG Injection</td><td>High</td><td>Used to trigger ovocyte maturation prior to insemination.</td><td>Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Nicolas Chevalier</td><td></td><td>Serum β-hCG Test Kits</td><td>Medium</td><td>Used to detect biochemical pregnancy rates post-insemination.</td><td>Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Nicolas Chevalier</td><td></td><td>Estradiol (E2) ELISA Kits</td><td>Medium</td><td>Used to measure E2 levels on the day of ovulation trigger to monitor ovarian response.</td><td>Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Nicolas Chevalier</td><td></td><td>Progesterone (PG) ELISA Kits</td><td>Medium</td><td>Used to measure progesterone levels on the day of trigger for cycle monitoring.</td><td>Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)</td><td>2025-12-21 03:09:10</td></tr>
    <tr><td>Nicolas Chevalier</td><td></td><td>LH (Luteinizing Hormone) ELISA Kits</td><td>Medium</td><td>Used to measure LH levels and detect spontaneous LH surge at the end of stimulation.</td><td>Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)</td><td>2025-12-21 03:09:10</td></tr>
  </table>
</body>
</html>
